Solid-State and Solution Characterization of Myricetin

Stephen J. Franklin, Paul B Myrdal

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Myricetin (MYR) is a natural compound that has been investigated as a chemopreventative agent. MYR has been shown to suppresses ultraviolet B (UVB)-induced cyclooxygenase-2 (COX-2) protein expression and reduce the incidence of UVB-induced skin tumors in mice. Despite MYR’s promise as a therapeutic agent, minimal information is available to guide the progression of formulations designed for future drug development. Here, data is presented describing the solid-state and solution characterization of MYR. Investigation into the solid-state properties of MYR identified four different crystal forms, two hydrates (MYR I and MYR II) and two metastable forms (MYR IA and MYR IIA). From solubility studies, it was evident that all forms are very insoluble (

Original languageEnglish (US)
Pages (from-to)1400-1408
Number of pages9
JournalAAPS PharmSciTech
Volume16
Issue number6
DOIs
StatePublished - Dec 1 2015

Fingerprint

myricetin
ultraviolet radiation
prostaglandin synthase
Cyclooxygenase 2
Solubility
crystals
solubility
protein synthesis
incidence
drugs
therapeutics
Skin
Incidence
mice

Keywords

  • hydrate
  • log P
  • myricetin
  • solubility
  • stability

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Solid-State and Solution Characterization of Myricetin. / Franklin, Stephen J.; Myrdal, Paul B.

In: AAPS PharmSciTech, Vol. 16, No. 6, 01.12.2015, p. 1400-1408.

Research output: Contribution to journalArticle

Franklin, Stephen J. ; Myrdal, Paul B. / Solid-State and Solution Characterization of Myricetin. In: AAPS PharmSciTech. 2015 ; Vol. 16, No. 6. pp. 1400-1408.
@article{b713bd713d254c2c845380c1501a897c,
title = "Solid-State and Solution Characterization of Myricetin",
abstract = "Myricetin (MYR) is a natural compound that has been investigated as a chemopreventative agent. MYR has been shown to suppresses ultraviolet B (UVB)-induced cyclooxygenase-2 (COX-2) protein expression and reduce the incidence of UVB-induced skin tumors in mice. Despite MYR’s promise as a therapeutic agent, minimal information is available to guide the progression of formulations designed for future drug development. Here, data is presented describing the solid-state and solution characterization of MYR. Investigation into the solid-state properties of MYR identified four different crystal forms, two hydrates (MYR I and MYR II) and two metastable forms (MYR IA and MYR IIA). From solubility studies, it was evident that all forms are very insoluble (",
keywords = "hydrate, log P, myricetin, solubility, stability",
author = "Franklin, {Stephen J.} and Myrdal, {Paul B}",
year = "2015",
month = "12",
day = "1",
doi = "10.1208/s12249-015-0329-6",
language = "English (US)",
volume = "16",
pages = "1400--1408",
journal = "AAPS PharmSciTech",
issn = "1530-9932",
publisher = "American Association of Pharmaceutical Scientists",
number = "6",

}

TY - JOUR

T1 - Solid-State and Solution Characterization of Myricetin

AU - Franklin, Stephen J.

AU - Myrdal, Paul B

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Myricetin (MYR) is a natural compound that has been investigated as a chemopreventative agent. MYR has been shown to suppresses ultraviolet B (UVB)-induced cyclooxygenase-2 (COX-2) protein expression and reduce the incidence of UVB-induced skin tumors in mice. Despite MYR’s promise as a therapeutic agent, minimal information is available to guide the progression of formulations designed for future drug development. Here, data is presented describing the solid-state and solution characterization of MYR. Investigation into the solid-state properties of MYR identified four different crystal forms, two hydrates (MYR I and MYR II) and two metastable forms (MYR IA and MYR IIA). From solubility studies, it was evident that all forms are very insoluble (

AB - Myricetin (MYR) is a natural compound that has been investigated as a chemopreventative agent. MYR has been shown to suppresses ultraviolet B (UVB)-induced cyclooxygenase-2 (COX-2) protein expression and reduce the incidence of UVB-induced skin tumors in mice. Despite MYR’s promise as a therapeutic agent, minimal information is available to guide the progression of formulations designed for future drug development. Here, data is presented describing the solid-state and solution characterization of MYR. Investigation into the solid-state properties of MYR identified four different crystal forms, two hydrates (MYR I and MYR II) and two metastable forms (MYR IA and MYR IIA). From solubility studies, it was evident that all forms are very insoluble (

KW - hydrate

KW - log P

KW - myricetin

KW - solubility

KW - stability

UR - http://www.scopus.com/inward/record.url?scp=84949090916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949090916&partnerID=8YFLogxK

U2 - 10.1208/s12249-015-0329-6

DO - 10.1208/s12249-015-0329-6

M3 - Article

C2 - 25986594

AN - SCOPUS:84949090916

VL - 16

SP - 1400

EP - 1408

JO - AAPS PharmSciTech

JF - AAPS PharmSciTech

SN - 1530-9932

IS - 6

ER -